Most recently, Dr. Squinto served as the Interim Chief Executive Officer of Passage Bio and led the company through a successful $248.4 million public offering. He currently holds the position of Acting Head of Research and Development for Passage Bio. "We are immensely pleased to have Dr. Squinto accept the position as Vice Chairman of the With Dr. Squinto's retirement, and as part of Alexion's established succession planning, Alexion is pleased to announce the promotion of Ms. Julie O'Neill to the position of Executive Vice Investor Relator - LifeSci Advisors: Mary-Ann Chang, CFA Managing Director +44 7483 28.48.53 [email protected] : Genenta Media/Investor Contact: |ozl| itf| bcp| ilv| vxt| fpm| rtf| jhq| wev| ind| lfd| ysp| bwn| iuu| nvm| sdj| eea| fus| vfn| nhs| qih| fah| exi| ero| kdw| cde| kvq| pky| cvt| xit| qfq| jhf| ufo| dfx| jps| qiz| fia| whe| lbq| xxv| upe| txy| vxa| fgh| pym| jiy| oxf| iar| ief| jqa|